American Association for Cancer Research

Table 1

Therapy of human pancreatic carcinoma growing in the pancreas of nude mice

Treatment group^a	Pancreatic tumors					Metastasis			Body weight (g)
		Incidence	Tumor volume (mm³)			Metastasis			Body weight (g)
			Median	Range	Liver	Lymph	Median	Range
Saline control	10/10^b	574	445–770	4/10^b	9/10^b	22	18–30
Gemcitabine	10/10	230^c	64–445	3/10	5/10	24	17–26
PKI 166, 7 days/wk	10/10	162^d	16–274	2/10	8/10	24	21–31
PKI 166, 7 days/wk + gemcitabine	10/10	18^d	6–80	0/10	1/10	18^e	15–24
PKI 166, 3 days/wk	10/10	174^c	88–607	1/10	7/10	25	21–31
PKI 166, 3 days/wk + gemcitabine	10/10	27^d	6–72	1/10	3/10	22	15–25

Treatment group^a	Pancreatic tumors					Metastasis			Body weight (g)
		Incidence	Tumor volume (mm³)			Metastasis			Body weight (g)
			Median	Range	Liver	Lymph	Median	Range
Saline control	10/10^b	574	445–770	4/10^b	9/10^b	22	18–30
Gemcitabine	10/10	230^c	64–445	3/10	5/10	24	17–26
PKI 166, 7 days/wk	10/10	162^d	16–274	2/10	8/10	24	21–31
PKI 166, 7 days/wk + gemcitabine	10/10	18^d	6–80	0/10	1/10	18^e	15–24
PKI 166, 3 days/wk	10/10	174^c	88–607	1/10	7/10	25	21–31
PKI 166, 3 days/wk + gemcitabine	10/10	27^d	6–72	1/10	3/10	22	15–25

L3.6pl human pancreatic cancer cells (1 × 10⁶) were injected into the pancreas of nude mice. Seven days later, groups of mice were treated with biweekly i.p. injections of gemcitabine (125 mg/kg) alone, daily or triweekly oral feedings of PKI 166 (50 mg/kg) alone, gemcitabine and PKI 166, or saline (control). All mice were killed on day 35.

Number of positive mice/number of mice injected.

P < 0.001 versus control.

P < 0.0001 versus control.

P < 0.01 versus control.

View Large

This Feature Is Available To Subscribers Only